References

• Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., . . . Mittendorf, E. A. (2019). Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncology, 5(8), 1205-1214. doi:10.1001/jamaoncol.2018. 7147 J JAMA Oncology
• Amagata, T., Rath, C., Rigot, J. F., Tarlov, N., Tenney, K., Valeriote, F. A., & Crews, P. (2003). Structures and Cytotoxic Properties of Trichoverroids and Their Macrolide Analogues Produced by Saltwater Culture of Myrothecium verrucaria. Journal of Medicinal Chemistry, 46(20), 4342-4350. doi:10.1021/jm030090t
• Aricò, E., Castiello, L., Capone, I., Gabriele, L., & Belardelli, F. J. C. (2019). Type I interferons and cancer: An evolving story demanding novel clinical applications. 11(12), 1943.
• Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., . . . Palucka, K. (2000). Immunobiology of Dendritic Cells. 18(1), 767-811. doi:10.1146/annurev. immunol.18.1.767
• Bondy, G. S., Pestka, J. J. J. J. o. T., & Reviews, E. H. P. B. C. (2000). Immunomodulation by fungal toxins. 3(2), 109-143.
• Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. J. E. r. (2019). Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. 40(1), 17-65.
• Chen, Daniel S., & Mellman, I. (2013). Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39(1), 1-10.
• Clevers, H., & Nusse, R. (2012). Wnt/β-Catenin Signaling and Disease. Cell, 149(6), 1192- 1205.
• Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. J. C. r. (2017). Innate immune signaling and regulation in cancer immunotherapy. 27(1), 96-108.
• Cruciat, C.-M., & Niehrs, C. (2013). Secreted and Transmembrane Wnt Inhibitors and Activators. 5(3). doi:10.1101/cshperspect.a015081
• Davis-Dusenbery, B. N., & Hata, A. (2010). Mechanisms of control of microRNA biogenesis. The Journal of Biochemistry, 148(4), 381-392. doi:10.1093/jb/mvq096 J the Journal of Biochemistry
• Dine, J., Gordon, R., Shames, Y., Kasler, M. K., & Barton-Burke, M. (2017). Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia- Pacific journal of oncology nursing, 4(2), 127-135. doi:10.4103/apjon.apjon_4_17
• Donaldson, B., Al-Barwani, F., Pelham, S. J., Young, K., Ward, V. K., & Young, S. L. J. J. f. i. o. c. (2017). Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. 5(1), 69.
• Esposito, A., Viale, G., & Curigliano, G. J. J. o. (2019). Safety, tolerability, and management of toxic effects of phosphatidylinositol 3- kinase inhibitor treatment in patients with cancer: a review. 5(9), 1347-1354.
• Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. J. A. J. o. H. (2019). An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. 94(S1), S3-S9.
• Focaccetti, C., Izzi, V., Benvenuto, M., Fazi, S., Ciuffa, S., Giganti, M. G., . . . Bei, R. J. I. j. o. m. s. (2019). Polyphenols as immunomodulatory compounds in the tumor microenvironment: friends or foes? , 20(7), 1714.
• Fu, Y., Li, F., Zhang, P., Liu, M., Qian, L., Lv, F., . . . Hou, R. (2019). Myrothecine A modulates the proliferation of HCC cells and the maturation of dendritic cells through downregulating miR-221. International Immunopharmacology, 75, 105783.
• Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. J. N. r. C. o. (2018). Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. 15(5), 325.
• Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G. V., Ciafrè, S. A., & Farace, M. G. (2007). miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1. 282(32), 23716- 23724. doi:10.1074/jbc.M701805200
• Goldsberry, W. N., Londoño, A., Randall, T. D., Norian, L. A., & Arend, R. C. (2019). A Review of the Role of Wnt in Cancer mmunomodulation. Cancers (Basel), 11(6). doi:10.3390/cancers11060771
• Goldsberry, W. N., Londoño, A., Randall, T. D., Norian, L. A., & Arend, R. C. J. C. (2019). A review of the role of Wnt in cancer immunomodulation. 11(6), 771.
• Gomez-Cadena, A., Urueña, C., Prieto, K., Martinez- Usatorre, A., Donda, A., Barreto, A., . . . disease. (2016). Immune-system- dependent anti-tumor activity of a plant- derived polyphenol rich fraction in a melanoma mouse model. 7(6), e2243- e2243.
• Green, D. S., Nunes, A. T., David-Ocampo, V., Ekwede, I. B., Houston, N. D., Highfill, S. L., . . . Zoon, K. C. J. J. o. t. m. (2018). A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron®(Peginterferon alfa- 2b) and Actimmune®(Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. 16(1), 196.
• Hafeez, U., Gan, H. K., & Scott, A. M. J. C. o. i. p. (2018). Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. 41, 114-121.
• Hanahan, D., & Weinberg, Robert A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646-674.
• Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., . . . Cong, F. (2012). ZNRF3 promotes Wnt receptor turnover in an R- spondin-sensitive manner. Nature, 485(7397), 195-200. doi:10.1038/nature11019
• Hu, Z., Ott, P. A., & Wu, C. J. J. N. R. I. (2018). Towards personalized, tumour-specific, therapeutic vaccines for cancer. 18(3), 168.
• June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. J. S. (2018). CAR T cell immunotherapy for human cancer. 359(6382), 1361-1365.
• Kagey, M. H., & He, X. (2017). Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. 174(24), 4637-4650.
• Kang, J., Demaria, S., & Formenti, S. J. J. f. i. o. c. (2016). Current clinical trials testing the combination of immunotherapy with radiotherapy. 4(1), 51.
• Kao, D., Flores-Bocanegra, L., Raja, H. A., Darveaux, B. A., Pearce, C. J., & Oberlies, N. H. (2020). New tricks for old dogs: Two new macrocyclic trichothecene epimers and absolute configuration of 16- hydroxyverrucarin B. Phytochemistry, 172, 112238.
• Kennedy, L. B., & Salama, A. K. J. C. a. c. j. f. c. (2020). A review of cancer immunotherapy toxicity. 70(2), 86-104.
• Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., . . . Research, C. C. (2019). Advances in cancer immunotherapy 2019-latest trends. 38(1), 1-11.
• Kusserow, A., Pang, K., Sturm, C., Hrouda, M., Lentfer, J., Schmidt, H. A., . . . Holstein, T. W. (2005). Unexpected complexity of the Wnt gene family in a sea anemone. Nature, 433(7022), 156-160. doi:10.1038/nature03158
• Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A.- L., Voron, T., Tartour, E., & Taieb, J. (2017). Immunomodulatory activity of VEGF in cancer. In International review of cell and molecular biology (Vol. 330, pp. 295-342): Elsevier.
• Liu, H.-X., Liu, W.-Z., Chen, Y.-C., Sun, Z.-H., Tan, Y.-Z., Li, H.-H., & Zhang, W.-M. (2016). Cytotoxic trichothecene macrolides from the endophyte fungus Myrothecium roridum. Journal of Asian Natural Products Research, 18(7), 684-689. doi:10.1080/10286020.2015.1134505
• Lohmueller, J., Finn, O. J. J. P., & therapeutics. (2017). Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. 178, 31-47.
• Mileo, A. M., Di Venere, D., Mardente, S., & Miccadei, S. (2020). Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS- Mediated Downregulation of Flap Endonuclease 1. Oxidative Medicine and Cellular Longevity, 2020, 7965435. doi:10.1155/2020/7965435
• Mileo, A. M., Nisticò, P., & Miccadei, S. J. F. i. i. (2019). Polyphenols: Immunomodulatory and therapeutic implication in colorectal cancer. 10, 729.
• Mullard, A. (2013). New checkpoint inhibitors ride the immunotherapy tsunami. Nature Reviews Drug Discovery, 12(7), 489-492. doi:10.1038/nrd4066
• Neufeld, G., Cohen, T., Gengrinovitch, S., & Poltorak, Z. J. T. F. j. (1999). Vascular endothelial growth factor (VEGF) and its receptors. 13(1), 9-22.
• Okazaki, T., & Honjo, T. (2007). PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology, 19(7), 813-824. doi:10.1093/intimm/dxm057 International Immunology
• Puzanov, I., Diab, A., Abdallah, K., Bingham, C., Brogdon, C., Dadu, R., . . . LeBoeuf, N. J. J. f. i. o. c. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. 5(1), 1-28.
• Rashdan, S., Minna, J. D., & Gerber, D. E. J. T. L. R. M. (2018). Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. 6(6), 472-478.
• Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. J. N. R. I. (2018). Complement in cancer: untangling an intricate relationship. 18(1), 5.
• Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. J. N. r. D. d. (2019). Delivery technologies for cancer immunotherapy. 18(3), 175-196.
• Rios-Esteves, J., & Resh, Marilyn D. (2013). Stearoyl CoA Desaturase Is Required to Produce Active, Lipid-Modified Wnt Proteins. Cell Reports, 4(6), 1072-1081.
• Rosa, V., Lucia, R., Pierlorenzo, P., Ivana De, M., Angelo, F., Vincenza, L., . . . Alfredo, F. (2007). MicroRNAs (miR)-221 and miR- 222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine- Related Cancer Endocr Relat Cancer, 14(3), 791-798. doi:10.1677/ERC-07-0129
• Shan, X., Li, S., Sun, B., Chen, Q., Sun, J., He, Z., & Luo, C. J. J. o. C. R. (2020). Ferroptosis- driven nanotherapeutics for cancer treatment. 319, 322-332.
• Sharpe, A. H. J. I. r. (2017). Introduction to checkpoint inhibitors and cancer immunotherapy. 276(1), 5.
• Steinman, R. M. (1991). The Dendritic Cell System and its Role in Immunogenicity. 9(1), 271- 296. doi:10.1146/annurev.iy.09.040191.00141 5
• Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. J. C. (2018). Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. 154(6), 1416-1423.
• Wang, B. X., & Fish, E. N. (2019). Global virus outbreaks: Interferons as 1st responders. Paper presented at the Seminars in immunology.
• Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. J. F. i. p. (2018). Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. 9, 185.
• Wilky, B. A. (2019). Immune checkpoint inhibitors: The linchpins of modern immunotherapy. 290(1), 6-23.
• Wirsdörfer, F., De Leve, S., & Jendrossek, V. J. I. J. o. M. S. (2019). Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity? 20(1), 24.
• Wu, Q., Wang, X., Nepovimova, E., Miron, A., Liu, Q., Wang, Y., . . . Kuca, K. (2017). Trichothecenes: immunomodulatory effects, mechanisms, and anti-cancer potential. Archives of Toxicology, 91(12), 3737-3785. doi:10.1007/s00204-017- 2118-3
• Xu, Z., Zhen, B., Park, Y., & Zhu, B. J. S. i. m. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. 36(4), 592- 605.
• Yamashita, R., Sato, M., Kakumu, T., Hase, T., Yogo, N., Maruyama, E., . . . Hasegawa, Y. (2015). Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. 4(4), 551-564.
• Zahavi, D., & Weiner, L. J. A. (2020). Monoclonal antibodies in cancer therapy. 9(3), 34.
• Zhang, R., Billingsley, M. M., & Mitchell, M. J. J. J. o. C. R. (2018). Biomaterials for vaccine- based cancer immunotherapy. 292, 256- 276.